<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Subcutaneous implantable cardioverter defibrillators</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Subcutaneous implantable cardioverter defibrillators</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Subcutaneous implantable cardioverter defibrillators</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bradley P Knight, MD, FACC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Samuel Lévy, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H963847716"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sudden cardiac death (SCD) resulting from cardiac arrhythmia is the world's leading cause of cardiovascular mortality, accounting for over 50 percent of cardiovascular deaths worldwide. Implantable cardioverter-defibrillators (ICDs) have been shown in numerous large clinical trials to reduce mortality from SCD in selected populations.</p><p>Traditionally, ICD systems consist of a pulse generator, typically placed in the pectoral region, and one or more leads that extend from the pulse generator to the myocardium via a transvenous route. However, conventional transvenous ICD (TV-ICD) systems have drawbacks, which include risks associated with insertion (eg, cardiac perforation, pericardial effusion) and persistence in the intravascular space (eg, endocarditis, lead fracture). </p><p>The subcutaneous ICD (S-ICD) has been developed in an attempt to eliminate some of the limitations of TV-ICD systems by avoiding endovascular access entirely  (<a class="graphic graphic_figure graphicRef97569" href="/z/d/graphic/97569.html" rel="external">figure 1</a> and <a class="graphic graphic_diagnosticimage graphicRef97372" href="/z/d/graphic/97372.html" rel="external">image 1</a>). </p><p>The S-ICD system, including its indications, efficacy, complications, and our approach to choosing the proper candidates for the S-ICD, will be discussed in detail here. </p><p>TV-ICD systems, including their potential complications, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/921.html" rel="external">"Implantable cardioverter-defibrillators: Overview of indications, components, and functions"</a>.)</p><p class="headingAnchor" id="H963847722"><span class="h1">S-ICD COMPONENTS AND CAPABILITIES</span><span class="headingEndMark"> — </span>Similar to a standard transvenous ICD (TV-ICD), the S-ICD is composed of a pulse generator and a lead  (<a class="graphic graphic_figure graphicRef97569" href="/z/d/graphic/97569.html" rel="external">figure 1</a> and <a class="graphic graphic_diagnosticimage graphicRef97372" href="/z/d/graphic/97372.html" rel="external">image 1</a>) [<a href="#rid1">1</a>]. In contrast to a standard TV-ICD, the pulse generator and lead have different characteristics and are placed in different positions. Both the pulse generator and the lead are larger than traditional TV-ICD systems. The pulse generator  (<a class="graphic graphic_figure graphicRef97569" href="/z/d/graphic/97569.html" rel="external">figure 1</a>) is implanted in a subcutaneous (or deeper) pocket in the lower left lateral or posterolateral thoracic position, and the lead is tunneled in the subcutaneous tissue from the pulse generator to a position along the left parasternal margin  (<a class="graphic graphic_picture graphicRef130973" href="/z/d/graphic/130973.html" rel="external">picture 1</a>). These characteristics of the S-ICD lead to differences in how it senses and treats ventricular tachycardia.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rhythm detection </strong>– The cardiac rhythm is detected via a wide bipole between the two sensing electrodes or between one of the sensing electrodes and the pulse generator [<a href="#rid2">2</a>]. The electrograms generated from these vectors are similar to the those produced by a surface ECG. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delivery of VT shocks </strong>– S-ICDs can deliver a maximum shock of 80 joules; however, in conversion testing, a successful conversion with 65 joules is considered to provide an adequate safety margin. Because of the higher energy requirement for defibrillation, and the relatively smaller experience with S-ICD compared with TV-ICD, conversion testing is generally recommended with all newly implanted S-ICDs. Despite this recommendation, conversion testing rates remain relatively low. In a study of 7900 patients in the National Cardiovascular Data Registry with S-ICD implanted between September, 2012 and April, 2016, only 71 percent underwent conversion testing [<a href="#rid3">3</a>]. In general, the need for defibrillation threshold (DFT) testing for TV-ICD is much less imperative. (See  <a class="medical medical_review" href="/z/d/html/921.html" rel="external">"Implantable cardioverter-defibrillators: Overview of indications, components, and functions", section on 'Defibrillation threshold testing'</a>.)</p><p></p><p class="bulletIndent1">The device delivers an 80-Joule shock for defibrillation of ventricular tachyarrhythmias including monomorphic ventricular tachycardia (VT), polymorphic VT, and ventricular fibrillation (VF). If VT or VF persists following the initial shock, the device will reverse polarity between the electrodes and deliver subsequent shocks. The S-ICD will deliver a maximum of five shocks for a single episode of a ventricular arrhythmia. If more than 3.5 seconds of asystole occurs following a shock, the S-ICD can deliver 30 seconds of demand pacing at a rate of 50 beats per minute. During an event, the S-ICD will store the electrocardiogram (ECG) tracing for subsequent review [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sensing </strong>–<strong> </strong>The sensing algorithm for S-ICD varies substantially from the algorithms used by TV-ICDs [<a href="#rid4">4</a>]. In general, arrhythmia detection and capacitor charging (to a much higher output) for S-ICD take longer than for TV-ICD.</p><p></p><p>The S-ICD can be implanted without the use of fluoroscopy by using anatomic landmarks to guide proper positioning. In practice, brief fluoroscopy is often used to guide placement of the lead as well as the generator. The mean procedure time for implantation of an S-ICD among first-time operators is 67±33 minutes in one study, and 55±23 minutes among operators who have inserted at least three S-ICDs [<a href="#rid2">2</a>]. This is comparable to the procedure length for TV-ICD at a similar time in their development, but may be longer than contemporary TV-ICD implant times for experienced operators [<a href="#rid5">5</a>]. The results from a small, nonrandomized observational series of patients suggest that DFT testing may not be required for all patients receiving the S-ICD, although additional data are required to reproduce and validate this result [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/921.html" rel="external">"Implantable cardioverter-defibrillators: Overview of indications, components, and functions", section on 'Defibrillation threshold testing'</a>.)</p><p>Initially, the S-ICD generator was placed subcutaneously in the mid to posterior axillary region. A posterior generator placement improves the shocking vector. Many implanters have moved to an intermuscular implant (between the serratus anterior and latissimus dorsi muscles) or submuscular implant. Advantages of these deeper implants include a lower shock impedance, higher likelihood of defibrillation success, and, in lean patients, a better cosmetic outcome. The implant procedure has evolved from three incisions (large pocket incision and smaller xiphoid and upper sternal incisions) to two, with the upper sternal incision usually omitted [<a href="#rid7">7,8</a>].</p><p class="headingAnchor" id="H2350889595"><span class="h1">INDICATIONS, CONTRAINDICATIONS, AND AN APPROACH TO SELECTING THE S-ICD</span><span class="headingEndMark"> — </span>S-ICDs were designed to address the limitations of conventional transvenous ICD (TV-ICD) systems, such as the need for vascular access. However, because of its unique capabilities and associated limitations, the S-ICD is not the best option for all patients requiring an ICD.</p><p>The number of patients who might potentially benefit from the S-ICD rather than a standard TV-ICD is not known  (<a class="graphic graphic_picture graphicRef104723" href="/z/d/graphic/104723.html" rel="external">picture 2</a>). In a retrospective single-center cohort study of 1345 patients who underwent ICD implantation for both primary and secondary indications, 463 patients (34 percent) received antitachycardia pacing as a therapy or developed an indication for bradycardia pacing or cardiac resynchronization therapy which cannot be performed using the S-ICD [<a href="#rid9">9</a>]. However, at five years of follow-up, 55 percent of the cohort would have been eligible for the S-ICD. On the other hand, when patients are properly selected, very few require revision of their device to allow for anti-tachycardia pacing or bradycardia pacing. </p><p class="headingAnchor" id="H963847728"><span class="h2">When to consider the S-ICD</span><span class="headingEndMark"> — </span>Our approach to selecting an S-ICD for a particular patient is in general agreement with recommendations from the 2017 American Heart Association/American College of Cardiology/Heart Rhythm Society guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death [<a href="#rid10">10</a>], and the 2015 European Society of Cardiology guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death [<a href="#rid11">11</a>]. S-ICDs are generally considered in the following situations:</p><p class="bulletIndent1"><span class="glyph">●</span>Younger patients (eg, age less than 45 years) with anticipated need for ICD therapy spanning decades (likely requiring multiple ICD systems over time). As examples, an S-ICD system might be an appropriate consideration in patients with hypertrophic cardiomyopathy, congenital cardiomyopathies, or inherited channelopathies. (See  <a class="medical medical_review" href="/z/d/html/119625.html" rel="external">"Hypertrophic cardiomyopathy: Management of ventricular arrhythmias and sudden cardiac death risk", section on 'Recommendations for ICD therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Candidates for an ICD without a current or anticipated need for bradycardia or antitachycardia pacing [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients at high risk for bacteremia, such as patients on hemodialysis or with chronic indwelling endovascular catheters.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with challenging vascular access or prior complications with TV-ICDs [<a href="#rid13">13,14</a>].</p><p></p><p>The S-ICD may also be an appealing option in children and teenagers who require an ICD, though data in this population are limited [<a href="#rid15">15,16</a>]. Although the contemporary S-ICD generator is substantially larger than a TV-ICD generator, the implant site and technique generally mitigate the importance of the size differential.</p><p class="headingAnchor" id="H2350889608"><span class="h2">When to avoid the S-ICD</span><span class="headingEndMark"> — </span>Aside from transient post-shock demand pacing, S-ICDs provide neither antitachycardia pacing as a therapy for ventricular arrhythmias nor continuous bradycardia pacing in the event of symptomatic bradyarrhythmias. Because of this, S-ICDs should not be implanted in patients who have monomorphic VT that is known or anticipated to be responsive to antitachycardia pacing or patients with the need for bradycardia pacing. Also related to the inability to provide chronic pacemaker activity, S-ICDs are also not indicated in patients requiring biventricular pacing for cardiac resynchronization therapy [<a href="#rid13">13,14</a>]. </p><p>Although there are limited published data, a small series suggests that the S-ICD can be expected to function normally within the presence of a preexisting permanent pacemaker functioning in a bipolar pacing mode [<a href="#rid12">12,17</a>]. Unipolar pacing from a coexisting device is contraindicated. Testing for device interactions is recommended at the S-ICD implant procedure.</p><p>A preimplantation surface ECG manual screening tool has also been developed to minimize the number of patients at risk for inappropriate shock (IAS) due to T-wave oversensing errors [<a href="#rid1">1,18,19</a>]. The tool identifies patients who have large and or late T-waves relative to the QRS using three vectors that mimic the device sensing vectors. ECG screening is available via automated software embedded on device programmers. Studies suggest that between 8 and 15 percent of patients are ineligible for an S-ICD due to susceptibility to T-wave oversensing and thus high risk of inappropriate shocks [<a href="#rid18">18,19</a>].</p><p class="headingAnchor" id="H1987665563"><span class="h2">Approach to S-ICD device selection</span><span class="headingEndMark"> — </span>While there are no absolute guidelines for the selection of a S-ICD over a TV-ICD system, our experts generally considered several clinical factors in deciding between the S-ICD and TV-ICD  (<a class="graphic graphic_algorithm graphicRef97368" href="/z/d/graphic/97368.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Does the patient have an indication for antitachycardia pacing or known to respond to antitachycardia pacing?</p><p class="bulletIndent1"><span class="glyph">●</span>Does the patient have an indication for standard transvenous pacing?</p><p class="bulletIndent1"><span class="glyph">●</span>Is the patient a candidate for biventricular pacing and cardiac resynchronization therapy?</p><p class="bulletIndent1"><span class="glyph">●</span>Is the patient relatively young with anticipated prolonged ICD therapy or multiple ICD systems in the course of one’s lifetime?</p><p class="bulletIndent1"><span class="glyph">●</span>Does the patient have other indwelling venous catheters or leads?</p><p class="bulletIndent1"><span class="glyph">●</span>Is the patient at high risk for systemic infection?</p><p></p><p>While there are no strict guidelines on the utilization of the S-ICD in place of a TV-ICD, the answers to the above questions can provide guidance to the clinician when discussing the situation with the patient. At present, battery longevity for TV-ICD substantially exceeds that of S-ICD, which presents both clinical and systems cost considerations.</p><p class="headingAnchor" id="H963847734"><span class="h1">S-ICD EFFICACY</span><span class="headingEndMark"> — </span>One randomized trial, and several nonrandomized studies, have evaluated the feasibility of an entirely S-ICD system, which was approved for use in the United States by the FDA in 2012 [<a href="#rid2">2,20-25</a>]. Successful detection of ventricular arrhythmias ranges from 98 to 100 percent, and conversion of induced arrhythmias during defibrillation threshold (DFT) testing ranges from 95 to 100 percent  (<a class="graphic graphic_table graphicRef97342" href="/z/d/graphic/97342.html" rel="external">table 1</a>), with a mean time to therapy as low as 14 seconds (slightly longer than typically seen with TV-ICDs) [<a href="#rid1">1,2,20-23,26-32</a>]. In a 2017 systematic review of 5380 patients from 16 studies, the pooled rate of successfully terminating ventricular arrhythmias was 96 percent [<a href="#rid31">31</a>].</p><p>Nonrandomized studies have generally shown efficacy and safety of the S-ICD.</p><p class="bulletIndent1"><span class="glyph">●</span>In the IDE trial, a prospective, nonrandomized, multicenter trial of patients with a standard indication for an ICD but no pacing requirement (mean age 52 years, 74 percent male, 79 percent primary prevention), 321 patients underwent S-ICD implantation and were followed for an average of 11 months [<a href="#rid26">26</a>]. Both primary endpoints were achieved, with a primary safety endpoint (180-day device and procedure-related complication free rate) of 92 percent and a primary efficacy endpoint (conversion of induced ventricular fibrillation at the time of implantation) of 100 percent among patients who completed the DFT testing protocol. Even when a sensitivity analysis was performed that assumed that all 17 of the 321 patients who did not complete DFT testing at the time of implantation would have failed defibrillation testing, the predetermined primary efficacy endpoint was still met. Following implantation, 21 patients (7 percent) received a total of 38 appropriate ICD shocks, while 41 patients (13 percent) received at least one inappropriate ICD shock.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Data from the EFFORTLESS S-ICD Registry, an observational study of 985 patients worldwide who have received the S-ICD (average follow-up 3.1 years), have shown complication-free rates of 96 and 92 percent at 30 and 360 days, respectively, with only 8 and 12 percent of patients having received an inappropriate shock at 1 year and 3.1 years, respectively [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar data have been reported from the S-ICD Post-Approval Study, a prospective registry involving 86 centers in the United States. Among 1637 patients who received the S-ICD, 1394 patients (99 percent) had successful termination of induced VT at the time of device insertion, with a 30-day complication-free rate of 96 percent [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the START (Subcutaneous versus Transvenous Arrhythmia Recognition Testing) trial, which compared simulated sensing performance of the S-ICD with that of standard transvenous ICDs (TV-ICDs) in 64 patients, both S-ICD and TV-ICD devices were successful in detecting 100 percent of ventricular arrhythmias [<a href="#rid34">34</a>]. In this trial, the S-ICD also had greater success in discriminating supraventricular tachycardias from VTs (98 percent S-ICD versus 76.7 percent for single-chamber TV-ICD versus 68 percent for dual-chamber TV-ICD).</p><p></p><p>Efficacy of S-ICD defibrillation can be maximized by optimal position of the device at the time of implantation [<a href="#rid35">35,36</a>]. A risk score (PRAETORIAN score) has been developed and validated based on the following determinants as identified on post-insertion posterior-anterior and lateral chest radiographs: subcoil fat, subgenerator fat, and anterior positioning of the S-ICD generator [<a href="#rid35">35</a>]. Higher amounts of fat between the coil and the sternum, higher amounts of fat between the generator and the rib cage, and more anterior generator position are associated with higher risk of failure to successfully defibrillate. A two incision implant technique with intermuscular placement (between anterior surface of serratus anterior and the posterior surface of latissimus dorsi) of the S-ICD generator has been generally adopted to achieve optimal posterior placement of the device and ideal cosmesis and patient comfort [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H963847740"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>The S-ICD system obviates many of the mechanical complications associated with transvenous lead implantation (eg, cardiac perforation leading to pericardial effusion and cardiac tamponade, hemothorax, pneumothorax, endovascular lead infection, venous occlusion). Additionally, the solid core design of the S-ICD lead and its lack of exposure to the repeated mechanical stresses of myocardial contraction may serve to improve lead durability when compared with TV-ICD leads [<a href="#rid4">4</a>]. However, the S-ICD system does have its own potential complications, including inappropriate shocks, pocket infection, and lead dislodgement or migration [<a href="#rid37">37</a>].</p><p>Among various publications on the S-ICD, the complication rate requiring reintervention has ranged from 1.3 to 19 percent [<a href="#rid1">1,2,4,20-23,25-29,31,38</a>].</p><p class="headingAnchor" id="H682251613"><span class="h2">Inappropriate shocks</span><span class="headingEndMark"> — </span>Inappropriate shocks (IAS) remain as one of the most common and concerning complications seen with S-ICDs, with most studies reporting an incidence ranging from 4 to 16 percent [<a href="#rid2">2,21-23,26-31,39</a>]. In a 2017 systematic review of 5380 patients from 16 studies, the pooled rate of inappropriate shocks was 4.3 percent [<a href="#rid31">31</a>]. Overall, the most common cause for IAS from S-ICDs is T-wave oversensing (TWOS), which differs from TV-ICD systems, in which most of the IAS are due to supraventricular arrhythmias or lead malfunction [<a href="#rid27">27,31,40,41</a>]. Inappropriate sensing of myopotentials from chest muscle activity may also be a source of IAS. IAS are more likely to occur in younger, physically active patients, who are also those commonly selected for placement of an S-ICD system [<a href="#rid20">20,27</a>].</p><p>The programming of an arrhythmia discrimination zone can reduce the frequency of inappropriate S-ICD shocks due to supraventricular arrhythmias [<a href="#rid26">26,42</a>]. In the S-ICD, this is called a conditional zone, in which discriminants are applied to prevent shocks due to rate only; in the faster zone, only rate is used for diagnosis. Conditional zone programming reduced the incidence of IAS caused by supraventricular arrhythmias by 70 percent (relative risk reduction) and those caused by TWOS by 56 percent [<a href="#rid26">26</a>]. In another study which compared 226 patients with dual-zone programming and 88 patients with single-zone programming, the two-year rates of freedom from IAS were 89.7 and 73.6 percent, respectively [<a href="#rid42">42</a>].</p><p>The morphology-based sensing algorithm was subsequently enhanced in an effort to reduce TWOS without sacrificing tachyarrhythmia detection. In a simulation using recorded TWOS episodes, as well as ventricular and supraventricular arrhythmias, the enhanced algorithm reduced inappropriate detection and device charging by 39.8 percent without a significant reduction in appropriate ventricular arrhythmia detections or specificity for supraventricular arrhythmias [<a href="#rid43">43</a>].</p><p>More recently, a high-pass filter (Smart Pass [SP]) was developed to further reduce IAS due to TWOS. In a study of 1984 patients, SP reduced first IAS by 50 percent and all IAS by 68 percent. There was no significant difference in rate of appropriate shocks or in time from arrhythmia onset to appropriate shock [<a href="#rid44">44</a>]. The SP feature has been available as a downloadable software upgrade to second-generation A209 devices since regulatory approval (United States: August, 2016; Europe: April, 2016), and is automatically enabled on contemporary A219 devices.</p><p>In UNTOUCHED, the IAS rate was studied in a contemporary primary prevention ICD population, utilizing contemporary S-ICD devices with standardized programming and contemporary discrimination algorithms. These 1111 patients had generation 2 or 3 devices, dual-zone programming (conditional zone 200 to 250 beats per minute), and SP enabled in 60 percent of patients. [<a href="#rid45">45</a>]. At 18 months, the incidence of IAS was 4.1 percent; this compares favorably to IAS rates in studies of contemporary TV-ICDs. Patients with generation 3 devices had a 53 percent reduction in IAS rates. The conversion success rate for appropriate discrete episodes was 98.4 percent. At 18 months, the device-related complication rate was 7.3 percent.</p><p class="headingAnchor" id="H4058261561"><span class="h2">Pocket hematoma</span><span class="headingEndMark"> — </span>The development of pocket hematoma requiring evacuation, transfusion, or extended hospital stay following S-ICD implantation is relatively low (reported rates of 1 to 5 percent) and similar to rates seen with TV-ICDs [<a href="#rid22">22,23,46</a>]. In a retrospective study of 200 patients who received the S-ICD at one of two academic medical centers, 10 patients (5 percent) developed a hematoma, with significantly greater likelihood in patients in whom antithrombotic therapy was uninterrupted or bridged with heparin (6 of 30 patients [20 percent] compared with 0 of 26 patients in whom antithrombotic therapy was stopped) [<a href="#rid46">46</a>]. Given the relatively small number of patients and events in this study, the optimal approach to management of antithrombotic and antiplatelet therapy in patients undergoing S-ICD implantation remains to be determined. However, our authors feel that the general approach to management anticoagulation with S-ICD implantation should be similar to that with TV-ICD implantation, namely avoiding the use of bridging anticoagulation with the consideration of device implantation on uninterrupted oral anticoagulation for patients at highest risk of thromboembolic events. (See  <a class="medical medical_review" href="/z/d/html/108919.html" rel="external">"Cardiac implantable electronic devices: Periprocedural complications", section on 'Bleeding'</a>.)</p><p class="headingAnchor" id="H1376280120"><span class="h2">Pocket infections</span><span class="headingEndMark"> — </span>While generally less concerning than infection involving TV-ICD systems, in which the indwelling venous leads pose a higher risk of systemic infection, pocket infections remain a concern with the S-ICD. Pocket infections have been noted in 1 to 10 percent of S-ICD recipients [<a href="#rid2">2,21,22,26,27,31,38</a>]. In a 2017 systematic review of 5380 patients from 16 studies, the pooled rate of pocket infection was 2.7 percent [<a href="#rid31">31</a>]. Complicated infections requiring device explantation are less frequent (1 to 4 percent of patients) [<a href="#rid23">23,26,27</a>]. Unlike the recommended course of therapy for an infected TV-ICD, S-ICD infections can be treated conservatively with a course of antibiotics and without removal of the S-ICD. Because the S-ICD device does not contain any endovascular leads, the risk of infection causing bacteremia/endocarditis is reduced, and in the event an S-ICD does require extraction, this procedure has less associated risk than transvenous lead extraction.</p><p class="headingAnchor" id="H1135150629"><span class="h2">Lead movement</span><span class="headingEndMark"> — </span>Lead dislodgement or migration had been noted to occur in 3 to 11 percent of patients in various studies [<a href="#rid2">2,21,29</a>]. Typically, lead dislodgement or migration is thought to result from vigorous physical activity occurring without adequate fixation of the parasternal lead and requires reoperation to reposition the lead [<a href="#rid2">2,21</a>]. Initially, the lead was fixed at both the xiphoid and upper sternal locations; this essentially eliminated lead dislodgement and migration [<a href="#rid21">21</a>]. The distal (upper sternal fixation) appears to be superfluous. In most patients, a single suture sleeve is used to anchor the lead near the xiphoid.</p><p class="headingAnchor" id="H3385887175"><span class="h2">Lead failure</span><span class="headingEndMark"> — </span>While it was anticipated that mechanical lead failure would be extraordinarily rare in S-ICD systems, a medical advisory was issued in December, 2020, describing a small number of lead fractures just distal to the proximal sense ring [<a href="#rid47">47</a>]. Mitigation strategies have been recommended. It was anticipated that extraction of chronically implanted S-ICD leads would be far more straightforward than for TV leads, which frequently require specialized extraction equipment due to intravascular scarring and fibrous adhesions (see  <a class="medical medical_review" href="/z/d/html/971.html" rel="external">"Cardiac implantable electronic device lead removal"</a>). Though experience thus far has been limited, in some cases, fibrous encapsulation of the subcutaneous lead has made extraction more difficult than expected [<a href="#rid48">48</a>]. In a French registry describing 32 patients, simple traction was successful in 19 patients, while three required an additional incision, and nine required a mechanical sheath to break up adhesions. In one patient, lead extraction was unsuccessful; the patient had undergone subsequent coronary artery bypass graft surgery, and the lead was inadvertently entrapped in a sternal wire [<a href="#rid49">49</a>].</p><p>Other less common complications that may require reintervention may include skin erosion, premature battery depletion, or explantation due to need for antitachycardia/bradycardia pacing or a new indication for resynchronization therapy [<a href="#rid21">21</a>]. In a cohort of 55 patients with the S-ICD who were followed for a median of 5.8 years, 26 patients (47 percent) underwent device replacement, with 25 of 26 patients requiring replacement for battery depletion [<a href="#rid50">50</a>]. The median time to replacement was five years, with five patients requiring replacement due to premature battery depletion within 18 months after implantation. At five years, 71 percent of devices were still in service.</p><p>Complication rates have been shown to improve as operators and centers gain experience with S-ICD implantation. In one study of 118 patients who underwent S-ICD implantation,<strong> </strong>adverse events were more frequent in the first 15 implantations per center compared with subsequent implantations (17 percent versus 10 percent with later implantations), suggesting significantly improved outcomes with center experience [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H963847746"><span class="h1">COMPARISON WITH TV-ICD</span><span class="headingEndMark"> — </span>One randomized trial and several nonrandomized studies have directly compared the efficacy of the S-ICD with traditional transvenous ICDs (TV-ICDs). A single nonblinded, randomized, noninferiority study compared S-ICD with TV-ICD [<a href="#rid51">51</a>]. In PRAETORIAN, 849 patients (81 percent primary prevention) who were felt appropriate for either type of device were randomized (426 S-ICD, 423 TV-ICD). The primary endpoint was a composite of device-related complications and inappropriate shocks (IAS). At median follow-up of 49.1 months, important results included:</p><p class="bulletIndent1"><span class="glyph">●</span>For the primary endpoint, S-ICD was noninferior to TV-ICD. Sixty-eight (15.1 percent) S-ICD patients and 68 (15.7 percent) TV-ICD patients had device-related complications or IAS (hazard ratio [HR] 0.99; 95% CI 0.71-1.39).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Device-related complications occurred in 31 S-ICD patients and 44 TV-ICD patients (HR 0.69; 95% CI 0.44-1.09).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>IAS occurred in 41 S-ICD patients and 29 TV- ICD patients (HR 1.43; 95% CI 0.89-2.30). Importantly, only 22 percent of the S-ICD patients had the Smart Pass (SP) filter active at the time of their first IAS, because of the era of patient enrollment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The secondary endpoint of death occurred in 83 S-ICD patients and 68 TV-ICD patients (HR 1.23; 95% CI 0.89-1.70). Sudden deaths were balanced in the two groups, but S-ICD patients had more nonsudden cardiovascular deaths and many more noncardiovascular deaths than TV-ICD patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The secondary endpoint of appropriate shocks occurred in 83 S-ICD patients and 57 TV-ICD patients (HR 1.52; 95% CI 1.08-2.12). This was largely due to the absence of antitachycardia pacing in the S-ICD patients; antitachycardia pacing terminated approximately half of the ventricular tachycardia episodes in the TV-ICD group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Similar mortality </strong>– A study from the National Cardiovascular Data Registry showed that among over 16,063 patients (mean age 73 years, 991 with S-ICD), there were no differences in mortality between patients with S-ICD and TV-ICD (incidence rates per 100 person years 12 versus 9; or in-hospital readmission 48 versus 38) [<a href="#rid52">52</a>]. Rates of complications, including device reoperation, device removal for infection, or other reasons, were also similar. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Similar rates of infection, device failure, and inappropriate therapies </strong>– A meta-analysis of five nonrandomized studies compared outcomes in S-ICD versus TV-ICD patients in over 6400 patients. Lead complications were fewer in S-ICD patients (odds ratio [OR] 0.13; 95% CI 0.05-0.38). There were no significant differences in infections (OR 0.75; 95% CI 0.30-1.89) or system/device failures (OR 1.13; 95% CI 0.43-3.02). Inappropriate therapies were similar (OR 0.87; 95% CI 0.51-1.49), though the causes were different. S-ICD patients were susceptible to inappropriate therapies due to T-wave oversensing and noise, while in TV-ICD patients, inappropriate therapies were more commonly due to supraventricular tachyarrhythmias, including atrial fibrillation [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1">In a retrospective cohort study of 1160 patients from two hospitals who received an ICD between 2005 and 2014 (including 148 who received an S-ICD between 2009 and 2014), propensity analysis was performed on 280 patients (140 S-ICD recipients and 140 matched TV-ICD recipients) [<a href="#rid53">53</a>]. The overall complication rate was not significantly different between the two groups (14 percent for S-ICD recipients versus 18 percent for TV-ICD recipients), with the S-ICD recipients experiencing significantly fewer lead-related complications (0.8 versus 11.5 percent) but significantly greater nonlead-related complications (9.9 versus 2.2 percent). While TV-ICD patients had significantly more ICD interventions (shocks plus antitachycardia pacing; HR 2.4), there was no significant difference in the frequency of shocks (both appropriate and inappropriate) between the two groups.</p><p></p><p class="headingAnchor" id="H1896391656"><span class="h1">FUTURE DIRECTIONS</span><span class="headingEndMark"> — </span>Limitations and complications related to endocardial leads have fueled the development of both S-ICD and leadless pacing (see  <a class="medical medical_review" href="/z/d/html/941.html" rel="external">"Permanent cardiac pacing: Overview of devices and indications", section on 'Leadless systems'</a>). It is likely that S-ICD will be paired with a leadless right ventricular pacemaker to allow antitachycardia pacing and bradycardia pacing. Leadless right atrial and left ventricular pacing are currently in development, raising the possibility of modular multichamber pacing and ICD systems in the future.</p><p class="headingAnchor" id="H67304912"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115372.html" rel="external">"Society guideline links: Heart failure in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/115586.html" rel="external">"Society guideline links: Ventricular arrhythmias"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/112356.html" rel="external">"Society guideline links: Cardiac implantable electronic devices"</a>.)</p><p class="headingAnchor" id="H2350890470"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15665.html" rel="external">"Patient education: Implantable cardioverter-defibrillators (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/82912.html" rel="external">"Patient education: Sudden cardiac arrest (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/3442.html" rel="external">"Patient education: Implantable cardioverter-defibrillators (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H963847758"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Components and capabilities of S-ICD </strong>– The subcutaneous (S-ICD) is composed of a pulse generator and single shocking coil running along the left parasternal margin  (<a class="graphic graphic_figure graphicRef97569" href="/z/d/graphic/97569.html" rel="external">figure 1</a> and <a class="graphic graphic_picture graphicRef130973" href="/z/d/graphic/130973.html" rel="external">picture 1</a> and <a class="graphic graphic_diagnosticimage graphicRef97372" href="/z/d/graphic/97372.html" rel="external">image 1</a>). These are both implanted subcutaneously  (<a class="graphic graphic_diagnosticimage graphicRef129617" href="/z/d/graphic/129617.html" rel="external">image 2</a> and <a class="graphic graphic_picture graphicRef131058" href="/z/d/graphic/131058.html" rel="external">picture 3</a>) without endovascular access. Implantation may be performed using anatomic landmarks without the use of fluoroscopy. (See <a class="local">'S-ICD components and capabilities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential drawbacks </strong>– Despite many well-documented benefits for appropriate patients, transvenous implantable cardioverter defibrillators (TV-ICDs) possess a number of drawbacks, which are most notably related to the reliance on endovascular leads. The subcutaneous ICD (S-ICD) has been developed in an attempt to minimize some of the limitations of TV-ICD systems by avoiding endovascular access entirely. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient selection </strong>– Appropriate patient selection for the S-ICD is continuing to evolve. However, S-ICDs may be considered in certain subsets of patients (see <a class="local">'Indications, contraindications, and an approach to selecting the S-ICD'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Younger patients due to the expected longevity of the implanted leads and a desire to avoid chronic transvenous leads</p><p class="bulletIndent2"><span class="glyph">•</span>Candi dates for an ICD without a current or anticipated need for pacing  (<a class="graphic graphic_figure graphicRef97569" href="/z/d/graphic/97569.html" rel="external">figure 1</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Patients at high risk for bacteremia, such as patients on hemodialysis or with chronic indwelling endovascular catheters</p><p class="bulletIndent2"><span class="glyph">•</span>Patients with challenging vascular access or prior TV-ICD complications</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications </strong>– While there are no defined guidelines for the selection of an S-ICD over a TV-ICD system, our approach in deciding between the S-ICD and TV-ICD is based on several clinical variables  (<a class="graphic graphic_algorithm graphicRef97368" href="/z/d/graphic/97368.html" rel="external">algorithm 1</a>). (See <a class="local">'Approach to S-ICD device selection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>– S-ICDs have proven to be very efficacious, with proper arrhythmia detection rates in &gt;99 percent of patients and successful spontaneous arrhythmia conversion rates of 88 percent on first shock (100 percent with a maximum of five shocks), both of which are comparable to rates seen with traditional TV-ICDs. (See <a class="local">'S-ICD efficacy'</a> above.) </p><p></p><p class="bulletIndent1">S-ICDs do not have the capability of providing continuous pacing; therefore, S-ICDs should not be utilized for patients requiring pacing, antitachycardia pacing, or cardiac resynchronization therapy. (See <a class="local">'When to avoid the S-ICD'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications </strong>– The S-ICD system does have its own potential complications, including inappropriate shocks, pocket infection, and lead dislodgement or migration. Inappropriate shocks appear to be the most common and concerning complication, but their frequency may be minimized by appropriate patient screening prior to implantation and appropriate device programming following implantation. (See <a class="local">'When to avoid the S-ICD'</a> above and <a class="local">'Complications'</a> above.)</p><p></p><p class="headingAnchor" id="H327252714"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff thank Jeffrey Selan, MD, Arjun Majithia, MD, Jonathan Weinstock, MD, FACC, FHRS, and Leonard Ganz, MD, FHRS, FACC, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">McLeod CJ, Boersma L, Okamura H, Friedman PA. The subcutaneous implantable cardioverter defibrillator: state-of-the-art review. Eur Heart J 2017; 38:247.</a></li><li><a class="nounderline abstract_t">Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med 2010; 363:36.</a></li><li><a class="nounderline abstract_t">Friedman DJ, Parzynski CS, Heist EK, et al. Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator: Report From the National Cardiovascular Data Registry. Circulation 2018; 137:2463.</a></li><li><a class="nounderline abstract_t">Poole JE. Novel ICD therapy begets novel ICD detection: first look at the performance of the subcutaneous ICD discrimination algorithm. Heart Rhythm 2014; 11:1359.</a></li><li><a class="nounderline abstract_t">Anvari A, Stix G, Grabenwöger M, et al. Comparison of three cardioverter defibrillator implantation techniques: initial results with transvenous pectoral implantation. Pacing Clin Electrophysiol 1996; 19:1061.</a></li><li><a class="nounderline abstract_t">Miller MA, Palaniswamy C, Dukkipati SR, et al. Subcutaneous Implantable Cardioverter-Defibrillator Implantation Without Defibrillation Testing. J Am Coll Cardiol 2017; 69:3118.</a></li><li><a class="nounderline abstract_t">Winter J, Siekiera M, Shin DI, et al. Intermuscular technique for implantation of the subcutaneous implantable cardioverter defibrillator: long-term performance and complications. Europace 2017; 19:2036.</a></li><li><a class="nounderline abstract_t">Brouwer TF, Miller MA, Quast AB, et al. Implantation of the Subcutaneous Implantable Cardioverter-Defibrillator: An Evaluation of 4 Implantation Techniques. Circ Arrhythm Electrophysiol 2017; 10:e004663.</a></li><li><a class="nounderline abstract_t">de Bie MK, Thijssen J, van Rees JB, et al. Suitability for subcutaneous defibrillator implantation: results based on data from routine clinical practice. Heart 2013; 99:1018.</a></li><li><a class="nounderline abstract_t">Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2018; 72:e91.</a></li><li><a class="nounderline abstract_t">Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015; 36:2793.</a></li><li><a class="nounderline abstract_t">Huang J, Patton KK, Prutkin JM. Concomitant Use of the Subcutaneous Implantable Cardioverter Defibrillator and a Permanent Pacemaker. Pacing Clin Electrophysiol 2016; 39:1240.</a></li><li><a class="nounderline abstract_t">Aziz S, Leon AR, El-Chami MF. The subcutaneous defibrillator: a review of the literature. J Am Coll Cardiol 2014; 63:1473.</a></li><li><a class="nounderline abstract_t">Majithia A, Estes NA 3rd, Weinstock J. Advances in sudden death prevention: the emerging role of a fully subcutaneous defibrillator. Am J Med 2014; 127:188.</a></li><li><a class="nounderline abstract_t">Pettit SJ, McLean A, Colquhoun I, et al. Clinical experience of subcutaneous and transvenous implantable cardioverter defibrillators in children and teenagers. Pacing Clin Electrophysiol 2013; 36:1532.</a></li><li><a class="nounderline abstract_t">Bettin M, Larbig R, Rath B, et al. Long-Term Experience With the Subcutaneous Implantable Cardioverter-Defibrillator in Teenagers and Young Adults. JACC Clin Electrophysiol 2017; 3:1499.</a></li><li><a class="nounderline abstract_t">Kuschyk J, Stach K, Tülümen E, et al. Subcutaneous implantable cardioverter-defibrillator: First single-center experience with other cardiac implantable electronic devices. Heart Rhythm 2015; 12:2230.</a></li><li><a class="nounderline abstract_t">Groh CA, Sharma S, Pelchovitz DJ, et al. Use of an electrocardiographic screening tool to determine candidacy for a subcutaneous implantable cardioverter-defibrillator. Heart Rhythm 2014; 11:1361.</a></li><li><a class="nounderline abstract_t">Randles DA, Hawkins NM, Shaw M, et al. How many patients fulfil the surface electrocardiogram criteria for subcutaneous implantable cardioverter-defibrillator implantation? Europace 2014; 16:1015.</a></li><li><a class="nounderline abstract_t">Jarman JW, Lascelles K, Wong T, et al. Clinical experience of entirely subcutaneous implantable cardioverter-defibrillators in children and adults: cause for caution. Eur Heart J 2012; 33:1351.</a></li><li><a class="nounderline abstract_t">Olde Nordkamp LR, Dabiri Abkenari L, Boersma LV, et al. The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort. J Am Coll Cardiol 2012; 60:1933.</a></li><li><a class="nounderline abstract_t">Köbe J, Reinke F, Meyer C, et al. Implantation and follow-up of totally subcutaneous versus conventional implantable cardioverter-defibrillators: a multicenter case-control study. Heart Rhythm 2013; 10:29.</a></li><li><a class="nounderline abstract_t">Lambiase PD, Barr C, Theuns DA, et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J 2014; 35:1657.</a></li><li><a class="nounderline abstract_t">Moore JP, Mondésert B, Lloyd MS, et al. Clinical Experience With the Subcutaneous Implantable Cardioverter-Defibrillator in Adults With Congenital Heart Disease. Circ Arrhythm Electrophysiol 2016; 9.</a></li><li><a class="nounderline abstract_t">León Salas B, Trujillo-Martín MM, García García J, et al. Subcutaneous implantable cardioverter-defibrillator in primary and secondary prevention of sudden cardiac death: A meta-analysis. Pacing Clin Electrophysiol 2019; 42:1253.</a></li><li><a class="nounderline abstract_t">Weiss R, Knight BP, Gold MR, et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation 2013; 128:944.</a></li><li><a class="nounderline abstract_t">Jarman JW, Todd DM. United Kingdom national experience of entirely subcutaneous implantable cardioverter-defibrillator technology: important lessons to learn. Europace 2013; 15:1158.</a></li><li><a class="nounderline abstract_t">Aydin A, Hartel F, Schlüter M, et al. Shock efficacy of subcutaneous implantable cardioverter-defibrillator for prevention of sudden cardiac death: initial multicenter experience. Circ Arrhythm Electrophysiol 2012; 5:913.</a></li><li><a class="nounderline abstract_t">Dabiri Abkenari L, Theuns DA, Valk SD, et al. Clinical experience with a novel subcutaneous implantable defibrillator system in a single center. Clin Res Cardiol 2011; 100:737.</a></li><li><a class="nounderline abstract_t">Burke MC, Gold MR, Knight BP, et al. Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry. J Am Coll Cardiol 2015; 65:1605.</a></li><li><a class="nounderline abstract_t">Chue CD, Kwok CS, Wong CW, et al. Efficacy and safety of the subcutaneous implantable cardioverter defibrillator: a systematic review. Heart 2017; 103:1315.</a></li><li><a class="nounderline abstract_t">Boersma L, Barr C, Knops R, et al. Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry: The EFFORTLESS Study. J Am Coll Cardiol 2017; 70:830.</a></li><li><a class="nounderline abstract_t">Gold MR, Aasbo JD, El-Chami MF, et al. Subcutaneous implantable cardioverter-defibrillator Post-Approval Study: Clinical characteristics and perioperative results. Heart Rhythm 2017; 14:1456.</a></li><li><a class="nounderline abstract_t">Gold MR, Theuns DA, Knight BP, et al. Head-to-head comparison of arrhythmia discrimination performance of subcutaneous and transvenous ICD arrhythmia detection algorithms: the START study. J Cardiovasc Electrophysiol 2012; 23:359.</a></li><li><a class="nounderline abstract_t">Quast ABE, Baalman SWE, Brouwer TF, et al. A novel tool to evaluate the implant position and predict defibrillation success of the subcutaneous implantable cardioverter-defibrillator: The PRAETORIAN score. Heart Rhythm 2019; 16:403.</a></li><li><a class="nounderline abstract_t">Amin AK, Gold MR, Burke MC, et al. Factors Associated With High-Voltage Impedance and Subcutaneous Implantable Defibrillator Ventricular Fibrillation Conversion Success. Circ Arrhythm Electrophysiol 2019; 12:e006665.</a></li><li><a class="nounderline abstract_t">Basu-Ray I, Liu J, Jia X, et al. Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Meta-Analysis of Case-Control Studies. JACC Clin Electrophysiol 2017; 3:1475.</a></li><li><a class="nounderline abstract_t">Brouwer TF, Driessen AHG, Olde Nordkamp LRA, et al. Surgical Management of Implantation-Related Complications of the Subcutaneous Implantable Cardioverter-Defibrillator. JACC Clin Electrophysiol 2016; 2:89.</a></li><li><a class="nounderline abstract_t">Kooiman KM, Knops RE, Olde Nordkamp L, et al. Inappropriate subcutaneous implantable cardioverter-defibrillator shocks due to T-wave oversensing can be prevented: implications for management. Heart Rhythm 2014; 11:426.</a></li><li><a class="nounderline abstract_t">Daubert JP, Zareba W, Cannom DS, et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 2008; 51:1357.</a></li><li><a class="nounderline abstract_t">Sharma D, Sharma PS, Miller MA, et al. Position and sensing vector-related triple counting and inappropriate shocks in the subcutaneous implantable cardioverter-defibrillator system. Heart Rhythm 2015; 12:2458.</a></li><li><a class="nounderline abstract_t">Gold MR, Weiss R, Theuns DA, et al. Use of a discrimination algorithm to reduce inappropriate shocks with a subcutaneous implantable cardioverter-defibrillator. Heart Rhythm 2014; 11:1352.</a></li><li><a class="nounderline abstract_t">Brisben AJ, Burke MC, Knight BP, et al. A new algorithm to reduce inappropriate therapy in the S-ICD system. J Cardiovasc Electrophysiol 2015; 26:417.</a></li><li><a class="nounderline abstract_t">Theuns DAMJ, Brouwer TF, Jones PW, et al. Prospective blinded evaluation of a novel sensing methodology designed to reduce inappropriate shocks by the subcutaneous implantable cardioverter-defibrillator. Heart Rhythm 2018; 15:1515.</a></li><li><a class="nounderline abstract_t">Gold MR, Lambiase PD, El-Chami MF, et al. Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. Circulation 2021; 143:7.</a></li><li><a class="nounderline abstract_t">Sheldon SH, Cunnane R, Lavu M, et al. Perioperative hematoma with subcutaneous ICD implantation: Impact of anticoagulation and antiplatelet therapies. Pacing Clin Electrophysiol 2018; 41:799.</a></li><li><a class="nounderline abstract_t">Kella DK, Stambler BS. Subcutaneous implantable cardioverter-defibrillator electrode fracture: Follow-up, troubleshooting, and evaluation. J Cardiovasc Electrophysiol 2021; 32:1452.</a></li><li><a class="nounderline abstract_t">Gutleben KJ, Nelovic V, Pujdak K, et al. Fracture of an S-ICD lead after two prior transvenous lead-related complications with conventional defibrillators. Pacing Clin Electrophysiol 2020; 43:1491.</a></li><li><a class="nounderline abstract_t">Behar N, Galand V, Martins RP, et al. Subcutaneous Implantable Cardioverter-Defibrillator Lead Extraction: First Multicenter French Experience. JACC Clin Electrophysiol 2020; 6:863.</a></li><li><a class="nounderline abstract_t">Theuns DA, Crozier IG, Barr CS, et al. Longevity of the Subcutaneous Implantable Defibrillator: Long-Term Follow-Up of the European Regulatory Trial Cohort. Circ Arrhythm Electrophysiol 2015; 8:1159.</a></li><li><a class="nounderline abstract_t">Knops RE, Olde Nordkamp LRA, Delnoy PHM, et al. Subcutaneous or Transvenous Defibrillator Therapy. N Engl J Med 2020; 383:526.</a></li><li><a class="nounderline abstract_t">Friedman DJ, Qin L, Parzynski C, et al. Longitudinal Outcomes of Subcutaneous or Transvenous Implantable Cardioverter-Defibrillators in Older Patients. J Am Coll Cardiol 2022; 79:1050.</a></li><li><a class="nounderline abstract_t">Brouwer TF, Yilmaz D, Lindeboom R, et al. Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy. J Am Coll Cardiol 2016; 68:2047.</a></li></ol></div><div id="topicVersionRevision">Topic 97158 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28182222" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The subcutaneous implantable cardioverter defibrillator: state-of-the-art review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20463331" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : An entirely subcutaneous implantable cardioverter-defibrillator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29463509" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator: Report From the National Cardiovascular Data Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24815524" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Novel ICD therapy begets novel ICD detection: first look at the performance of the subcutaneous ICD discrimination algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8823833" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comparison of three cardioverter defibrillator implantation techniques: initial results with transvenous pectoral implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28641801" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Subcutaneous Implantable Cardioverter-Defibrillator Implantation Without Defibrillation Testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28007749" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Intermuscular technique for implantation of the subcutaneous implantable cardioverter defibrillator: long-term performance and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28073910" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Implantation of the Subcutaneous Implantable Cardioverter-Defibrillator: An Evaluation of 4 Implantation Techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23704324" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Suitability for subcutaneous defibrillator implantation: results based on data from routine clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29097296" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26320108" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27734502" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Concomitant Use of the Subcutaneous Implantable Cardioverter Defibrillator and a Permanent Pacemaker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24530663" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The subcutaneous defibrillator: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24411409" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Advances in sudden death prevention: the emerging role of a fully subcutaneous defibrillator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24033753" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical experience of subcutaneous and transvenous implantable cardioverter defibrillators in children and teenagers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29759830" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Long-Term Experience With the Subcutaneous Implantable Cardioverter-Defibrillator in Teenagers and Young Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26073595" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Subcutaneous implantable cardioverter-defibrillator: First single-center experience with other cardiac implantable electronic devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24755323" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Use of an electrocardiographic screening tool to determine candidacy for a subcutaneous implantable cardioverter-defibrillator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24351884" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : How many patients fulfil the surface electrocardiogram criteria for subcutaneous implantable cardioverter-defibrillator implantation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22408031" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinical experience of entirely subcutaneous implantable cardioverter-defibrillators in children and adults: cause for caution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23062537" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23032867" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Implantation and follow-up of totally subcutaneous versus conventional implantable cardioverter-defibrillators: a multicenter case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24670710" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27635073" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical Experience With the Subcutaneous Implantable Cardioverter-Defibrillator in Adults With Congenital Heart Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31396970" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Subcutaneous implantable cardioverter-defibrillator in primary and secondary prevention of sudden cardiac death: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23979626" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23449924" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : United Kingdom national experience of entirely subcutaneous implantable cardioverter-defibrillator technology: important lessons to learn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22923274" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Shock efficacy of subcutaneous implantable cardioverter-defibrillator for prevention of sudden cardiac death: initial multicenter experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21416191" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical experience with a novel subcutaneous implantable defibrillator system in a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25908064" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28687562" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Efficacy and safety of the subcutaneous implantable cardioverter defibrillator: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28797351" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry: The EFFORTLESS Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28502872" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Subcutaneous implantable cardioverter-defibrillator Post-Approval Study: Clinical characteristics and perioperative results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22035049" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Head-to-head comparison of arrhythmia discrimination performance of subcutaneous and transvenous ICD arrhythmia detection algorithms: the START study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30292861" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A novel tool to evaluate the implant position and predict defibrillation success of the subcutaneous implantable cardioverter-defibrillator: The PRAETORIAN score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30917689" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Factors Associated With High-Voltage Impedance and Subcutaneous Implantable Defibrillator Ventricular Fibrillation Conversion Success.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29759827" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Meta-Analysis of Case-Control Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29766859" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Surgical Management of Implantation-Related Complications of the Subcutaneous Implantable Cardioverter-Defibrillator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24321235" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Inappropriate subcutaneous implantable cardioverter-defibrillator shocks due to T-wave oversensing can be prevented: implications for management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18387436" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26304714" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Position and sensing vector-related triple counting and inappropriate shocks in the subcutaneous implantable cardioverter-defibrillator system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24732366" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Use of a discrimination algorithm to reduce inappropriate shocks with a subcutaneous implantable cardioverter-defibrillator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25581303" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A new algorithm to reduce inappropriate therapy in the S-ICD system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29758404" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Prospective blinded evaluation of a novel sensing methodology designed to reduce inappropriate shocks by the subcutaneous implantable cardioverter-defibrillator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33073614" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29659027" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Perioperative hematoma with subcutaneous ICD implantation: Impact of anticoagulation and antiplatelet therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33694226" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Subcutaneous implantable cardioverter-defibrillator electrode fracture: Follow-up, troubleshooting, and evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33085093" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Fracture of an S-ICD lead after two prior transvenous lead-related complications with conventional defibrillators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32703570" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Subcutaneous Implantable Cardioverter-Defibrillator Lead Extraction: First Multicenter French Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26148819" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Longevity of the Subcutaneous Implantable Defibrillator: Long-Term Follow-Up of the European Regulatory Trial Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32757521" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Subcutaneous or Transvenous Defibrillator Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35300816" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Longitudinal Outcomes of Subcutaneous or Transvenous Implantable Cardioverter-Defibrillators in Older Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27810043" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
